About LyGenesis
LyGenesis is a company based in Pittsburgh (United States) founded in 2017 by Paulo Fontes and Michael Hufford.. LyGenesis has raised $27.85 million across 4 funding rounds from investors including Juvenescence, Prime Movers Lab and Longevity Vision Holding. LyGenesis offers products and services including LIV-001, Thymus Therapy, Kidney Therapy, and Pancreas Therapy. LyGenesis operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Terns Pharmaceutical, among others.
- Headquarter Pittsburgh, United States
- Founders Paulo Fontes, Michael Hufford
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lygenesis, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$27.85 M (USD)
in 4 rounds
-
Latest Funding Round
$19 M (USD), Series A
Oct 05, 2023
-
Investors
Juvenescence
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LyGenesis
LyGenesis offers a comprehensive portfolio of products and services, including LIV-001, Thymus Therapy, Kidney Therapy, and Pancreas Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapy for end-stage liver disease using lymph nodes.
Treatment for thymus-related aging and immune function.
Therapy for end-stage renal disease via organ regeneration.
Cell therapy for Type 1 diabetes management.
Unlock access to complete
Co Team
1 people
Operations Team
1 people
Leadership Team
1 people
CSO Team
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of LyGenesis
LyGenesis has successfully raised a total of $27.85M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $19 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $19.0M
-
First Round
First Round
(09 May 2018)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Series A - LyGenesis | Valuation | Prime Movers Lab | |
| Dec, 2020 | Amount | Series A - LyGenesis | Valuation |
investors |
|
| Oct, 2019 | Amount | Series A - LyGenesis | Valuation | Longevity Vision Fund |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in LyGenesis
LyGenesis has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Juvenescence, Prime Movers Lab and Longevity Vision Holding. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Support is provided for longevity breakthrough initiatives by Longevity Vision Holding.
|
Founded Year | Domain | Location | |
|
Venture capital firm funding breakthrough scientific startups and innovative sectors worldwide.
|
Founded Year | Domain | Location | |
|
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by LyGenesis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - LyGenesis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lygenesis Comparisons
Competitors of LyGenesis
LyGenesis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Terns Pharmaceutical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Therapies for liver disease and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics are developed for diseases with impaired kidney function.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lygenesis
Frequently Asked Questions about LyGenesis
When was LyGenesis founded?
LyGenesis was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is LyGenesis located?
LyGenesis is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Is LyGenesis a funded company?
LyGenesis is a funded company, having raised a total of $27.85M across 4 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on May 09, 2018.
What does LyGenesis do?
LyGenesis was founded in 2017 in Pittsburgh, United States, within the biotechnology sector focused on regenerative medicine. Organ regeneration technology is being developed by the company, utilizing patients own lymph nodes to regrow damaged organs. Preclinical studies have been completed for the lead program targeting end-stage liver disease, with operations centered on advancing treatments for liver disorders.
Who are the top competitors of LyGenesis?
LyGenesis's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
What products or services does LyGenesis offer?
LyGenesis offers LIV-001, Thymus Therapy, Kidney Therapy, and Pancreas Therapy.
Who are LyGenesis's investors?
LyGenesis has 3 investors. Key investors include Juvenescence, Prime Movers Lab, and Longevity Vision Holding.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.